<h3>Background:</h3> Ankylosing spondylitis (AS) mainly affects the spine and the sacroiliac joints, it is a chronic inflammatory disease that might be associated with a variety of extra spinal lesions involving the eyes, bowel, and skin. In Colombia little is known in regards of this condition. Spondyloarthritis (SpA) is one the most prevalent musculoskeletal disease in the Americas, with an estimated prevalence of 0.5%. This group of patients present a number of unmet needs for accessibility to the consultation, diagnosis and adequate treatments. That for this reason it is necessary to develop a program of Centers of Excellence (CoE) in this pathology, which allows answer to these needs and at the same time to add values for our health systems. <h3>Objectives:</h3> To describe the characteristics of patients with AS who attend to a specialized in SpA disease management model center. <h3>Methods:</h3> We implemented a pilot SpA program under the scheme of CoE, as they are already delineated in projects like REAL-PANLAR for rheumatoid arthritis. We performed a cross sectional study and reviewed the medical charts of patients with AS. All patients had a confirmed diagnosis of AS. We collected demographic data (age, sex, smoking, alcohol consumption); BASDAI, BASFI, DAS, disease specific data treatment with csDMARDs or bDMARDs and comorbidities, evaluation period covered January to December 2018. <h3>Results:</h3> During 2018 257 patients with AS entered to our program. 64% were men and 36% were female; mean age was 48 years ±14. 28% of our patients with SA had comorbidities the most common was high blood pressure 19% followed by diabetes mellitus 4%. Regarding behavioral habits 23% were current smokers and 11% reported to consume alcohol. When we evaluated clinical outcomes BASDAI mean score was 2.95 ± 2.06, BASFI mean score was 3.49 ± 2.36 and, ASDAS mean score was 1.70 ± 1.01. 60% of patients received biological DMARDs and 25% received conventional DMARDs. The remaining 15% received corticoids or pain medications. <h3>Conclusion:</h3> Due to the need to develop CESPAs, in order to define treatment targets type T2T-SpA, we implemented an innovative program in a low-income country with the aim to improve clinical outcomes and avoid so much disability and health economic costs. This descriptive data is the starting point to collect evidence and demonstrate the impact of the program <h3> Disclosure of Interests:</h3> Anggie Aza: None declared, Fernando Rodriguez: None declared, Pedro Santos-Moreno Grant/research support from: Dr Santos has received research grants from Janssen, Abbvie and UCB, Speakers bureau: Dr Santos has received speaker fees from Sanofi, Lilly, Bristol, Pfizer, Abbvie, Janssen and UCB, Diana Buitrago-Garcia: None declared